NGEN — Nervgen Pharma Share News
0.000.00%
Last trade - 00:00Brief: NervGen To Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
Brief: Nervgen Reports Second Quarter 2026 Financial Results And Provides Business Updates
Brief: Nervgen Pharma Corp - Nvg-291 Shows Statistically Significant Gait Quality Improvement In Phase 1B/2A Connect Sci Study
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers
U.S. STOCKS ON THE MOVE-NervGen Pharma, Medline, Silver miners
U.S. STOCKS ON THE MOVE-Estée Lauder, Perpetua Resources, Merck & Co
NervGen Pharma tumbles on deep-discounted $60 mln equity raise
Brief: Nervgen Says Co. Announces Pricing Of US$60.0 Million Public Offering Of Securities
NervGen Pharma tumbles on stock-and-warrants offering
U.S. STOCKS ON THE MOVE-UnitedHealth, Intel, Apple
U.S. STOCKS ON THE MOVE-Apple, Intel, Alignment Healthcare
U.S. STOCKS ON THE MOVE -Health insurers, Arista, Savara
NervGen rises after FDA backs late-stage study to test drug for spinal cord injury
Brief: Nervgen Pharma Announces Successful End-Of-Phase 2 Meeting And FDA Alignment On Restore, A Phase 3 Registrational Study Of Nvg-291 For Chronic Tetraplegia
Brief: Nervgen Pharma Reports Full Year 2025 Financial Results And Provides Business Updates